Equities

Gossamer Bio Inc

Gossamer Bio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.04
  • Today's Change0.080 / 8.36%
  • Shares traded2.39m
  • 1 Year change+17.08%
  • Beta1.9577
Data delayed at least 15 minutes, as of Sep 20 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy3
Outperform4
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Gossamer Bio Inc have a median target of 7.00, with a high estimate of 15.00 and a low estimate of 0.50. The median estimate represents a 566.67% increase from the last price of 1.05.
High1,328.6%15.00
Med566.7%7.00
Low-52.4%0.50

Earnings history & estimates in USD

On Aug 12, 2024, Gossamer Bio Inc reported 2nd quarter 2024 earnings of 0.22 per share. This result was in line with the consensus of the 10 analysts following the company and outperformed last year's 2nd quarter results by 0.67.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate+20.95%
Gossamer Bio Inc reported annual 2023 losses of -1.18 per share on Mar 05, 2024.
Average growth rate+18.45%
More ▼

Revenue history & estimates in USD

Gossamer Bio, Inc. had 2nd quarter 2024 revenues of 95.84m. This missed the 114.29m consensus estimate of the 7 analysts following the company.
Average growth rate0.00%
Gossamer Bio, Inc. did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.